Table 4 Medical consultation 40 to 56 days after boost COVID-19 vaccination separated by age group
Age < 55 years | Age ≥ 55 years | |||||
|---|---|---|---|---|---|---|
ChAdOx1/ ChAdOx1 | ChAdOx1/ mRNA | mRNA/ mRNA | ChAdOx1/ ChAdOx1 | ChAdOx1/ mRNA | mRNA/ mRNA | |
(n = 167) | (n = 1199) | (n = 3204) | (n = 295) | (n = 439) | (n = 1800) | |
Medical consultation, thereof... | 21 (12.6%) | 198 (16.5%) | 507 (15.8%) | 48 (16.3%) | 89 (20.3%) | 289 (16.1%) |
Outpatient | ||||||
Yes | 19 (90.5%) | 174 (87.9%) | 425 (83.8%) | 42 (87.5%) | 74 (83.1%) | 242 (83.7%) |
Planned | 2 (9.5%) | 24 (12.1%) | 76 (15.0%) | 4 (8.3%) | 12 (13.5%) | 41 (14.2%) |
No | 0 (0%) | 0 (0%) | 6 (1.2%) | 2 (4.2%) | 3 (3.4%) | 6 (2.1%) |
Inpatient/Clinic | ||||||
Yes | 3 (14.3%) | 13 (6.6%) | 49 (9.7%) | 10 (20.8%) | 8 (9.0%) | 36 (12.5%) |
Planned | 0 (0%) | 1 (0.5%) | 3 (0.6%) | 1 (2.1%) | 1 (1.1%) | 6 (2.1%) |
No | 18 (85.7%) | 184 (92.9%) | 455 (89.7%) | 37 (77.1%) | 80 (89.9%) | 247 (85.5%) |
Pre-existing conditions | ||||||
Yes | 2 (9.5%) | 30 (15.2%) | 61 (12%) | 9 (18.8%) | 10 (11.2%) | 42 (14.5%) |
Partially | 6 (28.6%) | 67 (33.8%) | 171 (33.7%) | 16 (33.3%) | 28 (31.5%) | 120 (41.5%) |
No | 13 (61.9%) | 101 (51.0%) | 275 (54.2%) | 23 (47.9%) | 51 (57.3%) | 127 (43.9%) |
Suspected association to vaccination | ||||||
Yes | 1 (4.8%) | 13 (6.6%) | 27 (5.3%) | 2 (4.2%) | 3 (3.4%) | 9 (3.1%) |
Partially | 5 (23.8%) | 43 (21.7%) | 116 (22.9%) | 5 (10.4%) | 17 (19.1%) | 55 (19%) |
No | 15 (71.4%) | 142 (71.7%) | 364 (71.8%) | 41 (85.4%) | 69 (77.5%) | 225 (77.9%) |